Company intelligence / Profile preview

TomaLab

Busto Arsizio, Lombardy, Italy

Ownership: Private
Development stage: Other

Overview

TomaLab provides advanced molecular diagnostic services focused on oncology, reproductive health, and rare diseases, using technologies like next-generation sequencing and real-time PCR. Strategic partnership with Mainz Biomed (2024) enables launch of ColoAlert®, a non-invasive, PCR-based colorectal cancer detection product for the Italian market.

Therapeutic areas: Women's HealthOncologyRare Diseases
Modalities: Molecular diagnostic assayPCR-based technologiesNext-generation sequencingCGH array platform
Industry: Molecular Diagnostics

Partnerships

Mainz Biomed (co-commercialization of ColoAlert® colorectal cancer test)

Beyond the preview

Go deeper on TomaLab.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TomaLab.

Explore the full profile